Hosted by Medscape · 🇺🇸 US · EN · 12 episodes
Established thought leaders with verified media credentials.
Listen to Medscape InDiscussion: Endometrial Cancer, a podcast series where thought leaders and clinical experts share their diverse insights and practical ideas for optimizing patient care. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999848. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Medscape hosts Medscape InDiscussion: Endometrial Cancer, a science show with 12 episodes published.
Drs Ursula A. Matulonis and Stephanie Lheureux discuss the importance of investigator-initiated clinical trials in endometrial cancer, research on carcinosarcoma, and ctDNA. Relevant disclosures can be found with the epi
Drs Ursula Matulonis and Jessica St. Laurent discuss endometrial cancer research, funding, early detection, and treatment, including the impact of GLP-1 receptor agonists. Relevant disclosures can be found with the episo
Drs Ursula A. Matulonis and David G. Mutch discuss past and present endometrial cancer research, including the Route 66 SPORE. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscap
Drs Ursula Matulonis and Brian Slomovitz discuss phase 3 trials of ADCs in endometrial cancer and what's to come in the field of endometrial cancer therapeutics. Relevant disclosures can be found with the episode show no
Drs Ursula A. Matulonis and Leif W. Ellisen discuss endometrial cancer and ADCs, including resistance mechanisms, ADC sequencing, what's exciting in the field, and novel payloads. Relevant disclosures can be found with t
Drs Ursula A. Matulonis and Joyce F. Liu discuss targeting DNA damage and repair and replication stress in endometrial cancer. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscap
Drs Ursula A. Matulonis and Gini Fleming discuss the state of endometrial cancer, the role of immunotherapy, and priorities for research in this field. Relevant disclosures can be found with the episode show notes on Med
Drs Ursula A. Matulonis and Katherine Fuh discuss the molecular classification and genetics of endometrial cancer as well as when to rebiopsy, research updates, and what's to come in the future. Relevant disclosures can
Drs Ursula A. Matulonis and Eloise Chapman-Davis discuss overcoming health disparities in endometrial cancer and increasing clinical trial enrollment of Black women. Relevant disclosures can be found with the episode sho
Drs Ursula A. Matulonis and Panagiotis A. Konstantinopoulos discuss hormonal therapy updates and different ways to target and treat ER+ metastatic endometrial cancer. Relevant disclosures can be found with the episode sh
Drs Ursula A. Matulonis and Akila N. Viswanathan discuss the role of radiation therapy in endometrial cancer, including staging, immunotherapy, and treatment disparities. Relevant disclosures can be found with the episod
Drs Ursula A. Matulonis and Mansoor Mirza discuss immunotherapy trials, novel therapies such as CDK4/6 inhibitors and antibody-drug conjugates, and shared decision-making. Relevant disclosures can be found with the episo
Drs Ursula A. Matulonis and Bhavana Pothuri discuss solutions to address health disparities in the diagnosis and treatment of endometrial cancer. Relevant disclosures can be found with the episode show notes on Medscape
Drs Ursula A. Matulonis and Joyce F. Liu discuss new therapeutics for patients with endometrial cancer, including ADCs, immunotherapy, and drugs targeting replication stress. Relevant disclosures can be found with the ep
Drs Ursula A. Matulonis and Alexi A. Wright discuss survivorship issues in endometrial cancer including sexual dysfunction, mental health, fatigue, and peripheral neuropathy. Relevant disclosures can be found with the ep
Drs Ursula A. Matulonis and Kathleen N. Moore discuss the different aspects of antibody-drug conjugates (ADCs) in endometrial cancer, medications that are currently available, and promising HER2 ADCs. Relevant disclosure
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
Medscape InDiscussion: Endometrial Cancer has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their science audience.
Medscape InDiscussion: Endometrial Cancer is hosted by Medscape. The show is categorised under science (health) and has published 12 episodes.
Medscape InDiscussion: Endometrial Cancer has published 12 episodes.
Medscape InDiscussion: Endometrial Cancer regularly covers science, health, fitness. It sits in the science category, with a health focus.
Medscape InDiscussion: Endometrial Cancer is accessible for guests with genuine science expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
Medscape InDiscussion: Endometrial Cancer hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of Medscape InDiscussion: Endometrial Cancer average 25 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates Medscape InDiscussion: Endometrial Cancer's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched yesterday.
